David Sinclair, Maintenance, and What Happens If You Stop

By
Published Updated Last reviewed
Medical lab testing image for David Sinclair, Maintenance, and What Happens If You Stop

At a glance

  • Celebrity: David Sinclair, Ph.D., Professor of Genetics at Harvard Medical School
  • Drug family: Longevity (NMN, metformin, resveratrol)
  • Status: Publicly confirmed use of all three compounds over multiple years
  • This page's focus: Discontinuation pharmacology and long-term maintenance considerations for each compound in Sinclair's public regimen

The Public Record: What Sinclair Has Confirmed

David Sinclair is not a celebrity who was caught with a prescription bottle. He is the academic architect of one of the most visible longevity movements in modern science, and he has been unusually transparent about self-experimentation.

In his 2019 bestseller Lifespan: Why We Age and Why We Don't Have To, Sinclair confirmed taking NMN (nicotinamide mononucleotide), resveratrol, and metformin daily. He reiterated this regimen in appearances on The Joe Rogan Experience, The Tim Ferriss Show, and lectures hosted by Harvard Medical School. In a widely shared tweet from January 2022, Sinclair listed his protocol: 1 gram of NMN each morning, 1 gram of resveratrol mixed with yogurt, and 800 mg of metformin at night.

By late 2023, Sinclair made public statements suggesting modifications to his regimen. In a podcast with Andrew Huberman, he indicated he had reduced or paused metformin on days he exercised, citing emerging data on metformin's potential to blunt exercise-induced mitochondrial adaptations. Whether additional changes have occurred since is not publicly confirmed as of this writing.

The HealthRX Medical Team treats everything above as confirmed. Sinclair's dosing specifics, any proprietary formulations he may use through his companies, and any unreported adjustments remain outside the public record.

NMN: What Stopping Looks Like

NMN is a precursor to nicotinamide adenine dinucleotide (NAD+), a coenzyme involved in hundreds of metabolic reactions. Sinclair's research at Harvard has centered on the hypothesis that declining NAD+ levels drive aging, and that replenishing NAD+ through precursors like NMN can slow or partially reverse age-related decline.

A 2022 randomized controlled trial published in Science demonstrated that NMN supplementation (250 mg/day) increased blood NAD+ levels and improved muscle insulin sensitivity in prediabetic women over 10 weeks. Separate trials in healthy middle-aged adults showed modest improvements in aerobic capacity.

Here is the discontinuation reality: NAD+ levels are not permanently altered by NMN supplementation. Preclinical data in mice show that NAD+ levels return to baseline within days to weeks after NMN is withdrawn. No human discontinuation trial has been published as of mid-2026, but the pharmacokinetics suggest a similar pattern. NMN has a short biological half-life. It is converted to NAD+ rapidly, and without continued dosing, NAD+ levels decline back toward pre-supplementation levels.

This means stopping NMN is unlikely to cause rebound effects or withdrawal symptoms. It also means any benefits are probably not sustained after cessation. The compound functions more like a daily nutritional input than a drug that permanently resets a biological pathway.

The HealthRX Medical Team take: NMN discontinuation is pharmacologically clean. There is no known rebound phenomenon. The more pressing question is whether years of supplementation produce durable epigenetic changes. Sinclair's own mouse reprogramming research hints at lasting cellular effects, but human evidence for permanent benefit from NMN alone does not yet exist. Patients stopping NMN should expect a gradual return to baseline NAD+ status over approximately one to four weeks.

Metformin: The Off-Label Longevity Drug with Real Discontinuation Data

Metformin is the one compound in Sinclair's regimen with decades of human safety data, though that data comes from its FDA-approved indication for type 2 diabetes, not longevity. The off-label longevity use is driven largely by observational findings. A 2014 analysis in Diabetes, Obesity and Metabolism found that diabetic patients on metformin had lower all-cause mortality than matched non-diabetic controls, a result that generated enormous interest in the aging research community.

The TAME trial (Targeting Aging with Metformin), designed to test metformin as an anti-aging intervention in non-diabetic older adults, has been in development since 2015. As of this writing, full results have not been published.

Discontinuation of metformin in diabetic patients is well characterized. Blood glucose regulation worsens within days. For non-diabetic users taking it off-label for longevity, the picture is different. There is no glucose dysregulation to "bounce back" from, since their glucose was presumably normal at baseline. Metformin's proposed longevity mechanisms, including AMPK activation and mTOR inhibition, are dose-dependent and reversible. Once the drug clears (half-life of roughly 5 hours), these pathways return to their default activity.

Sinclair's reported decision to skip metformin on exercise days reflects a legitimate concern. A 2019 study in Aging Cell found that metformin blunted improvements in VO2max and mitochondrial respiration when combined with aerobic exercise training. For someone using metformin specifically for longevity, attenuating exercise adaptations could undermine a primary goal.

The HealthRX Medical Team take: Stopping metformin in a non-diabetic person is straightforward from a safety perspective. There is no physiological dependence and no withdrawal syndrome. The real clinical question is whether intermittent dosing (skipping exercise days) preserves the theoretical longevity benefits while avoiding the exercise blunting effect. No trial has answered this specific question. Patients considering this strategy should discuss it with a physician who can monitor fasting glucose, insulin, and lactate levels.

Resveratrol: Limited Human Evidence, Clean Discontinuation

Resveratrol, a polyphenol found in grape skins and red wine, became central to Sinclair's public identity after his 2006 Nature paper showed it activated sirtuin pathways and extended lifespan in obese mice. He has confirmed taking 1 gram daily, mixed with fat (yogurt) to improve its notoriously poor oral bioavailability.

Human evidence for resveratrol's longevity effects remains thin. A meta-analysis in Clinical Nutrition found modest improvements in fasting glucose and insulin in diabetic subjects but no consistent benefit in healthy adults. A separate Cochrane-style review concluded that resveratrol's effects on cardiovascular biomarkers were small and inconsistent across trials.

Discontinuation of resveratrol is pharmacologically unremarkable. The compound has a plasma half-life of roughly 1 to 3 hours and is extensively metabolized by the liver. There is no accumulation with chronic use and no documented rebound effect. Stopping it is, from a clinical standpoint, equivalent to stopping any polyphenol supplement.

The HealthRX Medical Team take: Resveratrol is the weakest leg of the Sinclair tripod in terms of human clinical evidence. Stopping it carries no known risk. The more relevant consideration for long-term users is hepatic load. At 1 gram daily, resveratrol undergoes significant first-pass metabolism, and while liver toxicity at supplemental doses has not been demonstrated in trials lasting up to 12 months, data beyond that timeframe is sparse. Periodic liver function monitoring is reasonable for anyone taking gram-level polyphenol supplements chronically.

Long-Term Continuation: What the Literature Supports

For users who intend to continue a Sinclair-style regimen indefinitely, the clinical considerations shift from "can I stop safely?" to "what should I monitor?"

NMN lacks long-term human safety data beyond 12 months. The longest published trial ran 12 weeks. For a compound that Sinclair has reportedly taken for over a decade, this gap between personal practice and published evidence is substantial. Monitoring should include periodic NAD+ metabolite panels (available through specialty labs), liver and kidney function, and uric acid, since NAD+ metabolism feeds into purine pathways.

Metformin's long-term safety in diabetics is established over decades of use. Vitamin B12 deficiency is the most clinically significant long-term risk, affecting an estimated 5 to 10 percent of chronic users according to ADA guidelines. Annual B12 monitoring is standard practice. Lactic acidosis remains a rare but serious concern, primarily in patients with renal impairment.

Resveratrol at high doses warrants periodic liver enzyme checks and awareness of potential drug interactions, particularly with CYP3A4 substrates.

The Bigger Picture: Celebrity Scientist as N-of-1

Sinclair's openness about his regimen has done something unusual in longevity medicine. It has made a Harvard professor's self-experiment the de facto reference protocol for thousands of consumers. His willingness to disclose specific compounds and doses sets him apart from celebrities whose medication use surfaces through tabloid speculation.

The clinical reality, though, is that Sinclair's regimen is an n-of-1 experiment. His biological age testing, his biomarker panels, his genetic background: none of these are generalizable. The compounds he takes have varying levels of evidence, from metformin (strong observational data, pending interventional trial) to NMN (promising preclinical, early-stage human data) to resveratrol (underwhelming human translation despite strong preclinical signals).

The HealthRX Medical Team take: Sinclair's protocol is not a prescription. It is a public hypothesis being tested in real time by its architect. Patients interested in similar regimens should work with a physician who can order appropriate baseline labs, establish monitoring intervals, and adjust based on individual response rather than a celebrity scientist's self-reported results.

Frequently asked questions

›
›
›
›
›

References

  • Yi et al. "NMN supplementation increases NAD+ levels and improves muscle insulin sensitivity in prediabetic women." Science (2022). https://pubmed.ncbi.nlm.nih.gov/36227993/
  • Liao et al. "NMN supplementation enhances aerobic capacity in amateur runners." Journal of the International Society of Sports Nutrition (2022). https://pubmed.ncbi.nlm.nih.gov/35182418/
  • Mills et al. "Long-term administration of NMN mitigates age-associated physiological decline in mice." Cell Metabolism (2016). https://pubmed.ncbi.nlm.nih.gov/29514064/
  • Lu et al. "Reprogramming to recover youthful epigenetic information and restore vision." Nature (2020). https://pubmed.ncbi.nlm.nih.gov/36638795/
  • Bannister et al. "Can people with type 2 diabetes live longer than those without?" Diabetes, Obesity and Metabolism (2014). https://pubmed.ncbi.nlm.nih.gov/25041462/
  • Barzilai et al. "Metformin as a tool to target aging." Cell Metabolism (2016). https://pubmed.ncbi.nlm.nih.gov/31242299/
  • Konopka et al. "Metformin inhibits mitochondrial adaptations to aerobic exercise training in older adults." Aging Cell (2019). https://pubmed.ncbi.nlm.nih.gov/30548390/
  • Baur et al. "Resveratrol improves health and survival of mice on a high-calorie diet." Nature (2006). https://pubmed.ncbi.nlm.nih.gov/17086191/
  • Walle et al. "High absorption but very low bioavailability of oral resveratrol in humans." Drug Metabolism and Disposition (2004). https://pubmed.ncbi.nlm.nih.gov/21899444/
  • Liu et al. "Effect of resveratrol on glucose control and insulin sensitivity." Clinical Nutrition (2015). https://pubmed.ncbi.nlm.nih.gov/25529459/
  • Riche et al. "Analysis of safety from a human clinical trial with resveratrol." Clinical Toxicology (2019). https://pubmed.ncbi.nlm.nih.gov/29210129/
  • DeFronzo et al. "Metformin-associated lactic acidosis: current perspectives." Metabolism (2016). https://pubmed.ncbi.nlm.nih.gov/28776081/
  • Detampel et al. "Drug interaction potential of resveratrol." Drug Metabolism Reviews (2012). https://pubmed.ncbi.nlm.nih.gov/24102575/